Register for our free email digests:
Mylan Pharmaceuticals Inc.
www.mylanpharms.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mylan Pharmaceuticals Inc.
Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.
Biocon-CHAI Cancer Biosimilars Deal Promises Large Savings
Biocon Biologics strikes deal with the Clinton Health Access Initiative to provide cost-effective alternatives to pricey reference biologics, beginning with trastuzumab and pegfilgrastim. Savings of over 59% for buyers are expected in some cases.
US Federal Circuit Refuses To Rehear Arguments In Hatch-Waxman Venue Litigation
Mylan disputed Valeant's complaint in New Jersey federal court for improper venue, on the basis that Valeant firm had no relevant ties to New Jersey and the only alleged act of infringement – submission of the ANDA – did not occur there.
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Company Information
- Industry
- Pharmaceuticals